Phase 2
Completed N=20
A Comparison of NETSPOT Imaging Versus F-FDG-PET in Head and Neck Cancer Patients
Source: ClinicalTrials.gov NCT03602911 ↗Enrolled (actual)
20
Serious AEs
0.0%
Results posted
Mar 2025
Primary outcomePrimary: Detection and Staging of Head and Neck Squamous Cell Carcinoma Using Standard Uptake Value for NETSPOT Imaging — 7.21; 4.84; 2.87; 2.46 (SUV) volume (cm3)
Summary
This is a proof-of-concept trial to compare 18F-FDG-PET/CT with NETSPOT (68Ga-DOTA-TATE), a commercially available radiotracer packet that utilizes 68Ga to image SSTR-specific tissue.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Detection and Staging of Head and Neck Squamous Cell Carcinoma Using Standard Uptake Value for NETSPOT Imaging |
7.21; 4.84; 2.87; 2.46; 3.24 | — |
| SECONDARY Detection of Primary Site for Head and Neck Squamous Cell Carcinoma Using SUV Measurements With NETSPOT Imaging |
14.98; 7.59; 13.11; 5.96; 3.92 | — |
Eligibility Criteria
Inclusion Criteria
Patients with suspected or diagnosed HNSCC undergoing planned 18F FDG PET/CT at the time of primary diagnosis or after completion of treatment.
Exclusion Criteria
Inability to undergo 18F-FDG-PET/CT imaging due to medical comorbidities
Data sourced from ClinicalTrials.gov (NCT03602911). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.